Interdisciplinary Management of Perianal Crohn's Disease
被引:8
作者:
Lightner, Amy L.
论文数: 0引用数: 0
h-index: 0
机构:
Mayo Clin, Div Colon & Rectal Surg, 200 1st St Southwest, Rochester, MN 55905 USAMayo Clin, Div Colon & Rectal Surg, 200 1st St Southwest, Rochester, MN 55905 USA
Lightner, Amy L.
[1
]
Faubion, William A.
论文数: 0引用数: 0
h-index: 0
机构:
Mayo Clin, Div Gastroenterol, 200 1st St Southwest, Rochester, MN 55905 USAMayo Clin, Div Colon & Rectal Surg, 200 1st St Southwest, Rochester, MN 55905 USA
Faubion, William A.
[2
]
Fletcher, Joel G.
论文数: 0引用数: 0
h-index: 0
机构:
Mayo Clin, Div Radiol, 200 1st St Southwest, Rochester, MN 55905 USAMayo Clin, Div Colon & Rectal Surg, 200 1st St Southwest, Rochester, MN 55905 USA
Fletcher, Joel G.
[3
]
机构:
[1] Mayo Clin, Div Colon & Rectal Surg, 200 1st St Southwest, Rochester, MN 55905 USA
[2] Mayo Clin, Div Gastroenterol, 200 1st St Southwest, Rochester, MN 55905 USA
[3] Mayo Clin, Div Radiol, 200 1st St Southwest, Rochester, MN 55905 USA
Perianal disease is a common manifestation of Crohn's disease (CD) that results in significant morbidity and decreased quality of life. Despite several medical and surgical options, complex perianal CD remains difficult to treat. Before the advent of biologic therapy, antibiotics were the mainstay of medical treatment. Infliximab remains the most well-studied medical therapy for perianal disease. Surgical interventions are limited by the risk of nonhealing wounds and potential incontinence. When treatment options fail, fecal diversion or proctectomy may be necessary. Stem cell therapies may offer improved results and seem to be safe, but are not yet widely used.